Apr 02, 2020 - Both diseases involve an overactive immune system.
Apr 03, 2020 - Incyte (INCY) plans to work with the FDA for evaluating Jakafi in patients with COVID-19-associated cytokine storm.
Apr 08, 2020 - The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.
Apr 14, 2020 - Bausch (BHC) begins a clinical study on Virazole in combination with standard-of-care therapy to treat adults with respiratory distress due to COVID-19 in Canada.
Apr 20, 2020 - Novartis (NVS) announces FDA's approval to evaluate hydroxychloroquine in hospitalized patients with COVID-19 in a late-stage study. The company is evaluating several of its drugs to treat COVID-19.
Apr 28, 2020 - Incyte (INCY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Apr 07, 2020 - The race to introduce a vaccine and drug for COVID-19 is creating near-term opportunities, making the biotech sector a lucrative space for investments.
Apr 16, 2020 - Vanda (VNDA) and The Feinstein Institutes for Medical Research initiate enrollment in the phase III ODYSSEY study on tradipitant to treat inflammatory lung injury associated with COVID-19 infection.
Apr 17, 2020 - Treatment with Gilead's (GILD) experimental antiviral, remdesivir, shows rapid recoveries in fever and respiratory symptoms in COVID-19 patients in a Chicago hospital.
Apr 17, 2020 - Roche (RHHBY) develops Elecsys, a new serology test, for the detection of antibodies against SARS-CoV-2, the virus causing COVID-19. The company plans to launch the same early next month.